During the virtual 2020 annual meeting of the American Society of Clinical Oncology (ASCO), 8 presentations included (updated) data discussing Belantamab Mafodotin.
DREAMM-2
DREAMM-2 is an open label study of belantamab mafodotin. Patients in the trial had actively progressing multiple myeloma that had worsened despite current standard of care and were randomised to two arms to receive either 2.5 mg/kg or 3.4 mg/kg belantamab mafodotin Q3W. Overall, patients in DREAMM-2 had more advanced disease, poorer prognosis and performance status and also had a greater number of prior lines of therapy in comparison with patients in DREAMM-1, the first time in human study of belantamab mafodotin.
DREAMM-6
DREAMM-6 is an open label phase I/II study evaluating the safety, tolerability and efficacy of belantamab mafodotin when administered in combination with approved regimens of either lenalidomide plus dexamethasone (Len/Dex; Arm A) or Bor/Dex (Arm B) in patients with RRMM who have become refractory or relapsed after one or more prior lines of treatment. Part 1 of the study is a dose escalation phase to evaluate the safety and tolerability of up to three dose levels and up to two dosing schedules of belantamab mafodotin in combination Len/Dex or Bor/Dex. Part 2 will further evaluate the safety and preliminary clinical activity of belantamab mafodotin at selected dose levels and dosing schedules in combination with Len/Dex or Bor/Dex.
| Immuno-oncology | ||
| Abstract Name | Abstract | Session Title |
| Eliason L, Opalinska J, Martin ML, Correll J, Gutierrez B, Popat R. DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM). | e20531 | Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr e20531) | 10.1200/JCO.2020.38.15_suppl.e20531 [Abstract] |
| Popat R, Suvannasankha A, Kapetanakis V, Prawitz T, Sarri G, Hughes R, Wang F, et al. DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM). | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr e20527) | 10.1200/JCO.2020.38.15_suppl.e20527 [Abstract] | |
| Cohen AD, Trudel S, Lonial S, Libby EN, Lee HC, Besemer B, Facon T, Nooka AK, et al. DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics | #8541 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr 8541) | 10.1200/JCO.2020.38.15_suppl.8541 [Abstract] |
| Lee HC, Cohen AD, Chari A, Hultcrantz M, Nooka AK, Callander NS, Suvannasankha A, Badros A, et al. DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment | #8519 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr 8519) | 10.1200/JCO.2020.38.15_suppl.8519 [Abstract] |
| Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AA, Callander NS, et al. Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). | #8536 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr 8536) | 10.1200/JCO.2020.38.15_suppl.8536 [Abstract] |
| Richardson PG, Biswas S, Holkova B, Jackson N, Netherway T, Paul S, Ferron-Brady G, Yeakey A, et al. DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) | #TPS8552 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr TPS8552) | 10.1200/JCO.2020.38.15_suppl.TPS8552 [Abstract]
|
| Nooka AK, Stockerl-Goldstein K, Quach H, Forbes A, Mateos MV, Amit Khot, Tan A, Abonour R, et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). | #8502 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr 8502) | 10.1200/JCO.2020.38.15_suppl.8502 [Abstract] |
| Usmani SZ, Terpos E, Janowski W, Quach H, West S, Williams D, Dettman EJ, Ferron-Brady G, et al. DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd versus VRd Alone in Transplant-ineligible Newly Diagnosed Multiple Myeloma (TI NDMM) | #TPS8556 | Hematologic Malignancies—Plasma Cell Dyscrasia J Clin Oncol 38: 2020 (suppl; abstr TPS8556) | 10.1200/JCO.2020.38.15_suppl.TPS8556 |
